You are here

Phase III Trial of Satraplatin Launched in Patients With Hormone-Refractory Prostate Cancer

Martinsried/Munich (Germany) and U.S. Research Facilities in Waltham/Boston, Mass. and Princeton, N.J., September 2, 2003 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDax 30) today announced that it has received written confirmation from the FDA (U.S. Food and Drug Administration) that the Company may initiate a Phase 3 registrational trial with satraplatin plus prednisone in patients with hormone-refractory prostate cancer who have failed prior treatment with chemotherapy. This notification is the culmination of the Company's satisfactory completion of both a Special Protocol Assessment (SPA) and an "End of Phase 2" meeting with the FDA.

GPC Biotech requested a review of the Phase 3 clinical trial protocol under an SPA, part of procedures published by the FDA in 2002 to encourage a meaningful dialogue between the Agency and a drug developer prior to the initiation of registrational studies. Under this SPA program, the FDA evaluates whether the protocol for a clinical trial is adequate to meet scientific and regulatory requirements for marketing approval of the drug by the FDA. The satraplatin Phase 3 clinical trial protocol has now successfully completed this SPA process.

In addition, GPC Biotech held an "End of Phase 2" meeting with the FDA. The purposes of this type of meeting include: assessing the safety of the drug regimen to be tested in the Phase 3 trial, evaluating the Phase 3 plan, and identifying any additional information that will be needed to support a marketing application. The combination of this meeting and the SPA provided GPC Biotech the opportunity to hold comprehensive and meaningful discussions with the FDA about the many components that will eventually be part of its U.S. NDA (New Drug Application) filing.

The satraplatin registrational Phase 3 study will assess the safety and efficacy of satraplatin in combination with prednisone as a second-line chemotherapy regimen in patients with hormone-refractory prostate cancer (HRPC). This will be a multicenter, global, randomized study. It is modeled on the smaller Phase 3 trial successfully conducted by the EORTC (European Organization for Research and Treatment of Cancer), the results of which were presented at the ASCO (American Society of Clinical Oncology) Annual Meeting in June 2003 (see GPC Biotech press release dated June 3, 2003). The GPC Biotech Phase 3 registrational trial will compare satraplatin plus prednisone versus prednisone alone. Prednisone is a synthetic hormone often used to treat advanced prostate cancer.

The primary endpoint of the registrational trial for accelerated approval will be the time to disease progression. The study's objectives also will include the evaluation of pain control and survival, as well as an assessment of drug safety in this patient population.

"We are pleased to have received clearance from the FDA to proceed with the Phase 3 study. Our discussions with the FDA have been very constructive in developing the trial design, and we will continue to work closely with the Agency throughout the trial process," said Marcel Rozencweig, M.D., Senior Vice President, Drug Development of GPC Biotech. "Hormone-refractory prostate cancer represents an area of major unmet medical need. For patients with this disease who fail one chemotherapeutic regimen, there are currently no approved treatment options." Dr. Rozencweig continued, "Together with our colleagues at Spectrum Pharmaceuticals, GPC Biotech is moving forward aggressively with the development and registrational plans for satraplatin."

Prostate cancer is the most common cancer among men in the U.S. Over 220,000 new cases are projected for 2003, and an estimated one in six men is expected to develop prostate cancer in his lifetime. An estimated 100,000 patients in North America, Europe and Japan combined have hormone-refractory prostate cancer. For those patients failing hormone therapy, treatment currently involves a limited number of options, including chemotherapy. These options are usually only marginally effective. For those patients who fail first-line chemotherapy, there are currently no approved treatment regimens.

About Satraplatin:
Satraplatin is a member of the platinum family of compounds, but unlike platinum compounds currently on the market, satraplatin is orally administered. Phase 2 trials have been successfully completed in HRPC, as well as in other tumor types, including ovarian and small-cell lung cancer. Results from a randomized, 50-patient study in HRPC were presented at the ASCO Annual Meeting in June 2003. These data demonstrated statistical significance in time to disease progression, doubling progression-free survival. A registrational Phase 3 trial in HRPC is expected to begin in the near future. Satraplatin has already been studied in over 600 patients. Additional information on satraplatin can be found in the Drug Discovery and Development section of the Company's Web site at www.gpc-biotech.com.

Source: GPC Biotech

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs